在怀孕期间使用类似葡萄糖-1受体激动剂:一篇综述
Rosa F Drummond1, Karl E Seif1, E Albert Reece1
1Division of Maternal Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Maryland School of Medicine and Medical Center, Baltimore, MD.
American journal of obstetrics and gynecology
|August 24, 2024
概括
葡萄糖类-1受体激动剂 (GLP-1RA) 用于治疗2型糖尿病和肥胖症. 怀孕期间意外的孕期接触缺乏足够的数据来证实安全性,需要避孕.
科学领域:
- 药理学 药理学是指药理学的学科.
- 内分泌学 在内分泌学.
- 生殖健康 生殖健康
背景情况:
- 类似葡萄糖类-1受体激动剂 (GLP-1RA) 对2型糖尿病和肥胖有效.
- 由GLP-1RA诱导的减肥可以导致有不孕史的女性意外怀孕.
- 关于在怀孕期间经受孕GLP-1 RA暴露的安全性数据有限.
研究的目的:
- 审查当前关于对GLP-1RAs进行经受孕暴露的安全性的证据.
- 为在怀孕早期意外接触GLP-1RA的患者提供临床咨询信息.
主要方法:
- 对动物研究和人类观察数据的审查,包括病例报告,队列研究和基于人口的研究.
- 对一项大型观察性研究的分析,比较GLP-1RA和2型糖尿病怀孕期间的胰岛素暴露.
主要成果:
- 动物研究表明,后代可能有不良后果,包括生长限制和异常.
- 人类研究和病例报告没有显示出先天性异常的明确模式.
- 最近的一项大型队列研究发现,在经受孕期间暴露于GLP-1RA时,主要形的风险没有显著增加,但缺乏对血糖控制的数据.
结论:
- 没有足够的证据来最终预测周周接受GLP-1RA暴露对怀孕结果的影响.
- 孕产妇血糖控制对潜在不良影响的影响尚不清楚.
- 建议在服用GLP-1RA的患者中采取避孕措施,以防止意外怀孕.
关键词:
在PCOS中,PCOS是PCOS.堕胎堕胎堕胎堕胎堕胎堕胎堕胎堕胎糖尿病胎儿病变 - 糖尿病胎儿病变杜拉格卢胺是什么意思胚胎死亡 胚胎死亡脱氧化的使用方法胎儿的异常情况.胎儿死亡 胎儿死亡胎儿生长限制 限制胎儿生长葡萄糖类-1受体激动剂的葡萄糖类-1受体激动剂血糖控制 血糖控制 血糖控制过高血糖症 (hyperglycemia) 是一种胰岛素耐药性是一种胰岛素耐药性.利拉格卢提德 (liraglutide) 是一种葡萄糖类药物.李克辛的想法没有改变.主要的先天性形主要的先天性形.流产 流产 流产 流产肥胖 肥胖 肥胖 肥胖 肥胖 肥胖 肥胖 肥胖经过避孕的使用.塞马格卢提德 (semaglutide) 是一种可怕的药物.这种特异性是teratogenicity.这就是Tirzepatide.2 型糖尿病 2 型糖尿病意外怀孕是没有计划的.减肥 减肥 减肥 减肥 减肥 减肥更多相关视频
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
4.9K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.9K
Oral Hypoglycemic Agents: Biguanides and Glitazones
993
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
993
Oral Hypoglycemic Agents: Glinides
1.0K
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1.0K
Glucagon-like Receptor Agonists
1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Dipeptidyl Peptidase 4 Inhibitors
1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Hypoglycemia and Glucagon
1.3K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.3K


